MEDFUTURE - Research Center for Advanced Medicine, University of Medicine and Pharmacy Iuliu-Hatieganu, Marinescu 23 Street, Cluj-Napoca, Romania.
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Marinescu 23 Street, No. 23, 400337, Cluj-Napoca, Romania.
Mol Aspects Med. 2019 Dec;70:33-56. doi: 10.1016/j.mam.2019.09.004. Epub 2019 Sep 23.
MicroRNAs (miRNAs) have rapidly emerged as key molecules in cancer initiation and development, showing the capability to regulate pivotal oncogenic pathways. MiR-155 has gathered an increased attention especially in oncology, but also in non-malignanat pathologies. Nowadays, this noncoding RNA is one of the most important miRNAs in cancer, due to the extensive signaling network associated with it, implication in immune system regulation and also deregulation in disease states. Therefore, numerous research protocols are focused on preclinical modulation of miR-155 for therapeutic purposes, or investigation of its dynamic expression for diagnostic/prognostic assessments, with the final intention of bringing this miRNA into the clinical setting. This review comprehensively presents the extended role of miR-155 in cancer and other pathologies, where its expression is dysregulated. Finally, we assess the future steps toward miR-155 based therapeutics.
微小 RNA(miRNAs)已迅速成为癌症发生和发展的关键分子,显示出调节关键致癌途径的能力。miR-155 特别在肿瘤学领域以及非恶性疾病中引起了越来越多的关注。如今,由于与它相关的广泛信号网络、在免疫系统调节中的作用以及在疾病状态下的失调,这种非编码 RNA 是癌症中最重要的 miRNA 之一。因此,许多研究方案都集中在 miR-155 的临床前调节以用于治疗目的,或研究其动态表达以用于诊断/预后评估,最终目的是将这种 miRNA 引入临床环境。本综述全面介绍了 miR-155 在癌症和其他病理中失调表达的扩展作用。最后,我们评估了基于 miR-155 的治疗方法的未来步骤。